Activated protein C resistance and the FV:R506Q mutation in a random population sample -: Associations with cardiovascular risk factors and coagulation variables

被引:0
|
作者
Lowe, GDO
Rumley, A
Woodward, M
Reid, E
Rumley, J
机构
[1] Univ Glasgow, Royal Infirm, Dept Med, Glasgow G31 2ER, Lanark, Scotland
[2] Univ Reading, Dept Appl Stat, Reading RG6 2AH, Berks, England
[3] Univ Glasgow, Yorkhill Hosp, Dept Med Genet, Glasgow, Lanark, Scotland
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Activated protein C (APC) resistance, defined as a low APC ratio, is associated with the factor V mutation R(506)Q (factor V Leiden). APC ratio map also be influenced by other clinical and coagulation variables, which we studied in 460 men and 495 women aged 25-74 years, from a random population sample (Glasgow MONICA Survey). APC ratio correlated positively with APTT; and inversely with factor VIIIc, factor IXc, antithrombin activity, prothrombin F1+2 fragment, and thrombin-antithrombin complexes; but not with other coagulation variables. APC ratio decreased with age, but APTT did not. APC ratio and APTT were significantly lower in women versus men? and were significantly lower in users of oral contraceptives or hormone replacement therapy. The EV:R(506)Q mutation (prevalence 2.5%) was associated with lower APC ratio and protein C and S activities and with higher factor VIIIc levels; but not with increases in F1+2 fragment or thrombin-antithrombin complexes. APC ratio correlated inversely with total cholesterol and di astolic blood pressure; and in women with triglycerides, systolic blood pressure, and body mass index. Obesity was associated with a significantly lower APC ratio. In contrast, smoking markers correlated positively with APC ratio in men. These associations of APC ratio may be relevant to the increased risks of venous thrombosis with age, female sex, oestrogen use,obesity and high factor VIIIc levels. The association of APC resistance with elevated plasma levels of coagulation markers suggests that this phenotype represents an in vivo hypercoagulable state.
引用
收藏
页码:918 / 924
页数:7
相关论文
共 50 条
  • [31] The R306G and R506Q mutations in coagulation Factor V reveals additional cleavage sites for Activated Protein C in the R313-R321 region and at R505
    Dirven, Richard J.
    Vos, Hans L.
    Bertina, Rogier M.
    THROMBOSIS RESEARCH, 2010, 125 (05) : 444 - 450
  • [32] FVQ506 mutation and resistance to activated protein C as risk factors for the development of stroke in subjects free of other risk factor
    Makris, T
    Papazachou, O
    Krespi, R
    Hatzizacharias, A
    Papadopoulos, D
    Paizis, I
    Gialeraki, O
    Votteas, V
    EUROPEAN HEART JOURNAL, 2004, 25 : 604 - 604
  • [33] C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease
    Woodward, M
    Rumley, A
    Lowe, GDO
    Tunstall-Pedoe, H
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (01) : 135 - 141
  • [34] Activated protein C resistance and thrombosis:: Molecular mechanisms of hypercoagulable state due to FVR506Q mutation
    Dahlbäck, B
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1999, 25 (03): : 273 - 289
  • [35] Resistance to activated protein C (APC): Mutation at ARG(506) of coagulation factor V and vascular access thrombosis in haemodialysis patients
    Fodinger, M
    Mannhalter, C
    Pabinger, I
    Koizar, D
    Rintelen, C
    Horl, WH
    SunderPlassmann, G
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (04) : 668 - 672
  • [36] Major cardiovascular events are associated with increased incidence of resistance to activated protein C and FV Leiden mutation in well controlled hypertensives
    Makris, T
    Hatzizacharias, A
    Krespi, P
    Paizis, J
    Papadoppoulos, D
    Batzoglou, E
    Zilidis, A
    Votteas, V
    JOURNAL OF HYPERTENSION, 2003, 21 : S306 - S306
  • [37] Factor V:Q506 mutation -: Resistance to activated protein C (APC):: Clinical implications with respect to family screening
    Middeldorp, S
    van der Meer, J
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1998, 24 (04): : 363 - 366
  • [38] PEPTIDE-BOND CLEAVAGES AND LOSS OF FUNCTIONAL-ACTIVITY DURING INACTIVATION OF FACTOR VA AND FACTOR VA(R506Q) BY ACTIVATED PROTEIN-C
    NICOLAES, GAF
    TANS, G
    THOMASSEN, MCLGD
    HEMKER, HC
    PABINGER, I
    VARADI, K
    SCHWARZ, HP
    ROSING, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (36) : 21158 - 21166
  • [39] EFFECTS OF PROTEIN-S AND FACTOR XA ON PEPTIDE-BOND CLEAVAGES DURING INACTIVATION OF FACTOR VA AND FACTOR VA(R506Q) BY ACTIVATED PROTEIN-C
    ROSING, J
    HOEKEMA, L
    NICOLAES, GAF
    CHRISTELLA, M
    THOMASSEN, LGD
    HEMKER, HC
    VARADI, K
    SCHWARZ, HP
    TANS, G
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) : 27852 - 27858
  • [40] Different anticoagulant response to activated protein C (APC test) and to Agkistrodon contortix venom (ACV test) in a family with FV-R506Q substitution
    Gemmati, D
    Serino, ML
    Mari, R
    Verzola, I
    Moratelli, S
    Ballerini, G
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1997, 3 (03) : 168 - 173